Table 2 Overall survival and event-free survival
From: Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma
Overall survival | Event free survival | |||
|---|---|---|---|---|
Five-year (%) | P | Five-year (%) | P | |
Total patients | 43.5 ± 5.6 | N/A | 40.3 ± 5.9 | N/A |
Age | ||||
≤11(F), ≤12(M) | 39.8 ± 14.2 | 34.8 ± 18.2 | ||
12 to 14 (F), 13 to (M) | 47.6 ± 10.3 | 43.9 ± 11.2 | ||
15 to 39 (F), 16 to 39 (M) | 42.2 ± 7.5 | 39.1 ± 7.8 | ||
≥40 | 50.0 ± 35.4 | 0.396 | 37.5 ± 28.6 | 0.925 |
Gender | ||||
Male | 42.8 ± 6.4 | 37.8 ± 7.0 | ||
Female | 47.0 ± 10.8 | 0.104 | 46.2 ± 11.0 | 0.063 |
Location | ||||
Distal femur | 45.1 ± 8.1 | 38.6 ± 8.3 | ||
Proximal tibia | 45.9 ± 9.9 | 52.9 ± 10.7 | ||
Proximal humerus | 31.2 ± 45.7 | 66.7 ± 19.2 | ||
Proximal fibula | 25.0 ± 20.4 | 30.7 ± 17.1 | ||
Proximal femur | 50.0 ± 25.0 | 0 | ||
hip/pelvic | 0 | 0 | ||
Other | 57.1 ± 18.7 | 0.752 | 71.4 ± 17.1 | 0.696 |
Pathological fracture | ||||
Yes | 0 | 0 | ||
No | 46.7 ± 5.6 | 0.193 | 42.3 ± 5.9 | 0.759 |
Subtype | ||||
Osteoblast | 41.8 ± 5.9 | 39.2 ± 6.4 | ||
Chondroblastic | 35.2 ± 17.2 | 41.7 ± 19.9 | ||
Fibroblastic | 67.3 ± 27.0 | 66.7 ± 19.2 | ||
Other | 0 | 0.916 | 37.5 ± 28.6 | 0.723 |
Chemotherapy | ||||
Optimal chemotherapy | 65.3 ± 7.3 | 55.0 ± 9.0 | ||
Suboptimal chemotherapy | 30.8 ± 6.9 | 0.006* | 31.1 ± 7.4 | 0.005* |
Local recurrence | ||||
Yes | 23.2 ± 12.0 | — | ||
No | 49.3 ± 6.1 | 0.135 | — | — |
Distal metastasis | ||||
Yes | 18.2 ± 8.8 | 0.001* | — | |
No | 61.5 ± 6.5 | — | — | |